ITMI20020681A0 - Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina - Google Patents

Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina

Info

Publication number
ITMI20020681A0
ITMI20020681A0 IT2002MI000681A ITMI20020681A ITMI20020681A0 IT MI20020681 A0 ITMI20020681 A0 IT MI20020681A0 IT 2002MI000681 A IT2002MI000681 A IT 2002MI000681A IT MI20020681 A ITMI20020681 A IT MI20020681A IT MI20020681 A0 ITMI20020681 A0 IT MI20020681A0
Authority
IT
Italy
Prior art keywords
paclitaxel
procedure
production
albumin nanoparticles
nanoparticles
Prior art date
Application number
IT2002MI000681A
Other languages
English (en)
Inventor
Maurizio Zenoni
Simone Maschio
Original Assignee
Acs Dobfar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of ITMI20020681A0 publication Critical patent/ITMI20020681A0/it
Priority to IT2002MI000681A priority Critical patent/ITMI20020681A1/it
Application filed by Acs Dobfar Spa filed Critical Acs Dobfar Spa
Priority to EP03004629A priority patent/EP1348431A1/en
Priority to AU2003200920A priority patent/AU2003200920A1/en
Priority to IL15476203A priority patent/IL154762A0/xx
Priority to NZ524605A priority patent/NZ524605A/en
Priority to US10/383,639 priority patent/US20030185894A1/en
Priority to ZA200302040A priority patent/ZA200302040B/xx
Priority to JP2003070028A priority patent/JP4794115B2/ja
Priority to MXPA03002543A priority patent/MXPA03002543A/es
Priority to BR0300846-0A priority patent/BR0300846A/pt
Priority to KR10-2003-0019242A priority patent/KR20030078722A/ko
Priority to RU2003108821/15A priority patent/RU2003108821A/ru
Priority to CA002423915A priority patent/CA2423915A1/en
Priority to CNA2006100770064A priority patent/CN1911446A/zh
Priority to NO20031448A priority patent/NO334407B1/no
Priority to CNB031083617A priority patent/CN1259902C/zh
Publication of ITMI20020681A1 publication Critical patent/ITMI20020681A1/it
Priority to US11/334,004 priority patent/US20060121119A1/en
Priority to JP2011043799A priority patent/JP2011132253A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
IT2002MI000681A 2002-03-29 2002-03-29 Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina ITMI20020681A1 (it)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IT2002MI000681A ITMI20020681A1 (it) 2002-03-29 2002-03-29 Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
EP03004629A EP1348431A1 (en) 2002-03-29 2003-03-03 Process for producing nanoparticles of paclitaxel and albumin
AU2003200920A AU2003200920A1 (en) 2002-03-29 2003-03-05 Process for producing nanoparticles of paclitaxel and albumin
IL15476203A IL154762A0 (en) 2002-03-29 2003-03-05 Process for producing nanoparticles of paclitaxel and albumin
NZ524605A NZ524605A (en) 2002-03-29 2003-03-07 Process for producing nanoparticles of paclitaxel and albumin
US10/383,639 US20030185894A1 (en) 2002-03-29 2003-03-10 Process for producing nanoparticles of paclitaxel and albumin
ZA200302040A ZA200302040B (en) 2002-03-29 2003-03-13 Process for producing nanoparticles of paclitaxel and albumin.
JP2003070028A JP4794115B2 (ja) 2002-03-29 2003-03-14 パクリタキセルおよびアルブミンのナノ粒子を作製する方法
MXPA03002543A MXPA03002543A (es) 2002-03-29 2003-03-24 Proceso para producir nanoparticulas de paclitaxel y albumina.
BR0300846-0A BR0300846A (pt) 2002-03-29 2003-03-26 Processo para produzir nanopartìculas de paclitaxel e albumina
KR10-2003-0019242A KR20030078722A (ko) 2002-03-29 2003-03-27 파클리탁셀 및 알부민의 나노입자의 제조방법
RU2003108821/15A RU2003108821A (ru) 2002-03-29 2003-03-28 Способ получения наночастиц паклитаксела и альбумина
CA002423915A CA2423915A1 (en) 2002-03-29 2003-03-28 Process for producing nanoparticles of paclitaxel and albumin
CNA2006100770064A CN1911446A (zh) 2002-03-29 2003-03-28 制备紫杉醇和白蛋白的纳米颗粒的方法
NO20031448A NO334407B1 (no) 2002-03-29 2003-03-28 Fremgangsmåte for fremstilling av et sterilt, lyofilisert pulver bestående av nanopartikler av paclitaxel og humant serumalbumin
CNB031083617A CN1259902C (zh) 2002-03-29 2003-03-28 制造紫杉醇和白蛋白的纳米颗粒的方法
US11/334,004 US20060121119A1 (en) 2002-03-29 2006-01-17 Process for producing nanoparticles of paclitaxel and albumin
JP2011043799A JP2011132253A (ja) 2002-03-29 2011-03-01 パクリタキセルおよびアルブミンのナノ粒子を作製する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI000681A ITMI20020681A1 (it) 2002-03-29 2002-03-29 Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina

Publications (2)

Publication Number Publication Date
ITMI20020681A0 true ITMI20020681A0 (it) 2002-03-29
ITMI20020681A1 ITMI20020681A1 (it) 2003-09-29

Family

ID=11449619

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002MI000681A ITMI20020681A1 (it) 2002-03-29 2002-03-29 Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina

Country Status (15)

Country Link
US (2) US20030185894A1 (it)
EP (1) EP1348431A1 (it)
JP (2) JP4794115B2 (it)
KR (1) KR20030078722A (it)
CN (2) CN1259902C (it)
AU (1) AU2003200920A1 (it)
BR (1) BR0300846A (it)
CA (1) CA2423915A1 (it)
IL (1) IL154762A0 (it)
IT (1) ITMI20020681A1 (it)
MX (1) MXPA03002543A (it)
NO (1) NO334407B1 (it)
NZ (1) NZ524605A (it)
RU (1) RU2003108821A (it)
ZA (1) ZA200302040B (it)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1023050B1 (en) * 1997-06-27 2013-09-25 Abraxis BioScience, LLC Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN105288630A (zh) * 2005-02-18 2016-02-03 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US20100278725A1 (en) * 2005-08-12 2010-11-04 Jiang Liu Methods and devices for lymphatic targeting
RU2451510C2 (ru) * 2005-08-31 2012-05-27 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
BRPI0615292A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
EP1870649A1 (en) 2006-06-20 2007-12-26 Octapharma AG Lyophilisation targetting defined residual moisture by limited desorption energy levels
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2008334547B2 (en) * 2007-12-13 2011-06-30 Novartis Ag Organic compounds
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP2156823A1 (en) * 2008-08-14 2010-02-24 Pharmatex Italia Srl Process for the preparation of sterile powdered pharmeceutical compounds in the form of micro and nanoparticles
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
BRPI1012525A2 (pt) 2009-04-15 2018-07-10 Abraxis Bioscience, Llc. composições de nanopatículas isentas de príons e métodos para sua fabricação
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
EP2521539A4 (en) * 2009-12-31 2014-11-26 Mannkind Corp INJECTABLE PREPARATIONS FOR PARENTERAL ADMINISTRATION
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
SG10201906075VA (en) 2010-03-29 2019-08-27 Abraxis Bioscience Llc Methods of treating cancer
KR100971087B1 (ko) * 2010-05-06 2010-07-16 김현수 불투명부에 암막기능을 갖는 블라인드지의 제직방법
SG186112A1 (en) 2010-06-04 2013-01-30 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
CN102274190B (zh) * 2010-06-11 2012-12-05 上海现代药物制剂工程研究中心有限公司 一种注射用紫杉醇白蛋白亚微粒及其制备方法
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂
DK2790675T3 (da) 2011-12-14 2019-09-09 Abraxis Bioscience Llc Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler
RU2014141615A (ru) 2012-03-16 2016-05-10 Тайхо Фармасьютикал Ко., Лтд. Новое противоопухолевое средство, включающее комбинацию трех агентов
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
US9962373B2 (en) 2013-03-14 2018-05-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
SG10202107198SA (en) 2015-06-29 2021-08-30 Abraxis Bioscience Llc Methods of treating epithelioid cell tumors
CN105012251A (zh) * 2015-08-24 2015-11-04 吉林大学 注射用紫杉烷类药物白蛋白纳米粒冻干制剂及制备方法
RU2021128415A (ru) * 2016-09-06 2021-11-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
JP6959661B2 (ja) 2016-09-27 2021-11-02 アイエムジーティー カンパニー リミテッド 抗癌剤を担持したヒト血清アルブミンナノ粒子を利用した肝動脈化学塞栓術用組成物およびその製造方法
WO2018081520A1 (en) * 2016-10-27 2018-05-03 Zhuhai Beihai Biotech Co., Ltd. Neutral ph compositions of docetaxel and human serum albumin
WO2019183146A1 (en) 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
CN108524452A (zh) * 2018-05-08 2018-09-14 辽宁大学 一种紫杉醇白蛋白纳米粒的制备方法和应用
CN110496111B (zh) * 2018-05-18 2021-07-23 国家纳米科学中心 一种白蛋白纳米复合结构及其制备方法和应用
CA3158764A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN110585444A (zh) * 2019-10-31 2019-12-20 董军 一种中西医结合药物及其制备方法与应用
CN114681408B (zh) * 2020-12-26 2023-06-23 四川汇宇制药股份有限公司 白蛋白结合型紫杉醇纳米粒的制备方法
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
GB202401848D0 (en) 2024-02-11 2024-03-27 Univ College Dublin Nat Univ Ireland Dublin Albumin nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5498421A (en) * 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
DE69833487T9 (de) * 1997-06-12 2007-03-01 Innovata Plc, Ruddington Polymer-wirkstoff-konjugate zur behandlung von krebs
EP1023050B1 (en) * 1997-06-27 2013-09-25 Abraxis BioScience, LLC Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU5241199A (en) * 1998-07-30 2000-02-21 Novopharm Biotech Inc. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
SK14452002A3 (sk) * 2000-04-10 2003-07-01 Teva Pharmaceutical Industries Ltd. Liečivo na liečenie rakoviny
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Also Published As

Publication number Publication date
JP2003300878A (ja) 2003-10-21
NO20031448L (no) 2003-09-30
CN1259902C (zh) 2006-06-21
US20060121119A1 (en) 2006-06-08
US20030185894A1 (en) 2003-10-02
JP2011132253A (ja) 2011-07-07
JP4794115B2 (ja) 2011-10-19
EP1348431A1 (en) 2003-10-01
IL154762A0 (en) 2003-10-31
NZ524605A (en) 2004-03-26
RU2003108821A (ru) 2004-11-10
CN1448128A (zh) 2003-10-15
CN1911446A (zh) 2007-02-14
CA2423915A1 (en) 2003-09-29
NO20031448D0 (no) 2003-03-28
BR0300846A (pt) 2004-08-17
MXPA03002543A (es) 2005-08-26
ZA200302040B (en) 2003-09-17
NO334407B1 (no) 2014-02-24
ITMI20020681A1 (it) 2003-09-29
AU2003200920A1 (en) 2003-10-16
KR20030078722A (ko) 2003-10-08

Similar Documents

Publication Publication Date Title
ITMI20020681A0 (it) Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
DE60310339D1 (de) Querträger und Herstellungsverfahren
DE60302362D1 (de) Hochleistungslaserdiode und herstellungsverfahren
ITPD20020316A1 (it) Dispositivo e metodo per la creazione di fullereni e/o nanotubi
DE60334632D1 (de) Mechanolumineszenzstoff und dessen herstellung
GB0304623D0 (en) Methods for the fabrication of nanoscale structures and semiconductor devices
DE60302916D1 (de) Halbleiterlaser und Herstellungsverfahren
DE60236994D1 (de) Halbleiterbauelement und dessen Herstellungsverfahren
ITMI20010859A0 (it) Procedimento integrato per la produzione di ossidi olefinici
ITFI20010103A0 (it) Metodo ed attrezzatura per la produzione di mattonelle monostrato
ITBO20030349A1 (it) Procedimento e macchina per la produzione di scatole di
DE60332140D1 (de) Halbleiterlaserbauelement und dessen herstellungsverfahren
DE602004005527D1 (de) Oberflächenemittierender Halbleiterlaser und dessen Herstellungsverfahren
ITMI20042139A1 (it) Procedimento per la produzione di cefepime e cefaposporine analoghe
ITMI20030811A1 (it) Procedimento ed impianto per la produzione di confezioni
ITMI20021739A1 (it) Procedimento ed apparecchiatura per la produzione di
DE60300306D1 (de) Halbleiter-Nanopartikel und deren Herstellungsmethode
ITMI20030346A1 (it) Procedimento per la produzione di mesitilene.
ITMI20032105A1 (it) Procedimento e dispositivo per la produzione di parti
ITTE20030003A1 (it) Procedimento per la realizzazione di stampi e/o matrici
ITBO20020094A0 (it) Procedimento per la realizzazione di composizioni ed apparecchiatura realizzante tale procedimento
ITMI20021429A1 (it) Procedimento per la realizzazione di piastrelle e piastrella ottenibile mediante tale procedimento
ITMI20011435A0 (it) Procedimento per la produzione di benzossazine e nuove benzossasine
ITTO20030567A1 (it) Procedimento ed apparecchiatura per la produzione di un
ITBO20030267A1 (it) Metodo ed apparecchiatura per la realizzazione di articoli